NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $12.00
Forecasted Upside: 206.91 %
Number of Analysts: 1
Breakdown:
0 Sell Ratings
0 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$3.91 As of 06/14/2021 01:00 AM ET

▼ -0.04 (-1.01%)

1 month | 3 months | 12 months

Get New Brainstorm Cell Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BCLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCLI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$12.00

▲ +206.91% Upside Potential

This price target is based on 1 analysts offering 12 month price targets for Brainstorm Cell Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 206.91% upside from the last price of $3.91.

Buy

The current consensus among 1 contributing investment analysts is to buy stock in Brainstorm Cell Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
1 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/4/2021	Maxim Group	Upgrade	Hold ➝ Buy	$12.00	High	i
11/17/2020	Maxim Group	Downgrade	Buy ➝ Hold		N/A	i
7/8/2020	Maxim Group	Boost Price Target	Buy	$9.00 ➝ $20.00	Low	i Rating by Jason McCarthy at Maxim Group
5/8/2020	Maxim Group	Initiated Coverage	Buy	$9.00	Medium	i Rating by Jason McCarthy at Maxim Group
11/15/2019	Maxim Group	Reiterated Rating	Buy	$9.00	Low	i Rating by Jason McCarthy at Maxim Group
10/11/2019	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Jason McCarthy at Maxim Group
5/14/2019	Maxim Group	Reiterated Rating	Buy	$9.00	Low	i Rating by Caroline Palomeque at Maxim Group
3/28/2019	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Caroline Palomeque at Maxim Group
1/22/2019	Maxim Group	Reiterated Rating	Buy	$9.00	Medium	i Rating by Caroline Palomeque at Maxim Group
12/26/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Caroline Palomeque at Maxim Group
12/18/2018	Dawson James	Reiterated Rating	Buy		High	i Rating by J. Kolbert at Dawson James
12/17/2018	Maxim Group	Reiterated Rating	Buy	$9.00	High	i Rating by Caroline Palomeque at Maxim Group
11/19/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Caroline Palomeque at Maxim Group
10/29/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Caroline Palomeque at Maxim Group
10/29/2018	HC Wainwright	Set Price Target	Buy	$11.00	High	i Rating by Jason Kolbert at HC Wainwright
10/3/2018	Maxim Group	Set Price Target	Buy	$9.00	Medium	i Rating by Caroline Palomeque at Maxim Group
9/18/2018	HC Wainwright	Set Price Target	Buy	$11.00	High	i Rating by Jason Kolbert at HC Wainwright
9/13/2018	Maxim Group	Reiterated Rating	Buy	$9.00	Low	i Rating by Caroline Palomeque at Maxim Group
8/27/2018	HC Wainwright	Set Price Target	Buy	$11.00	Low	i Rating by Jason Kolbert at HC Wainwright
7/24/2018	HC Wainwright	Set Price Target	Buy	$11.00	High	i Rating by Jason Kolbert at HC Wainwright
7/23/2018	Maxim Group	Set Price Target	Buy	$9.00	Medium	i Rating by Caroline Palomeque at Maxim Group
7/8/2018	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Caroline Palomeque at Maxim Group
7/2/2018	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Caroline Palomeque at Maxim Group
6/26/2018	HC Wainwright	Reiterated Rating	Buy	$11.00	Low	i Rating by Jason Kolbert at HC Wainwright
6/8/2018	HC Wainwright	Set Price Target	Buy	$11.00	Low	i Rating by Jason Kolbert at HC Wainwright
5/29/2018	HC Wainwright	Set Price Target	Buy	$11.00	High	i Rating by J. Kolbert at HC Wainwright
5/25/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Jason McCarthy at Maxim Group
5/15/2018	HC Wainwright	Initiated Coverage	Buy	$11.00	High	i Rating by J. Kolbert at HC Wainwright
5/14/2018	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Jason McCarthy at Maxim Group
3/28/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Jason McCarthy at Maxim Group
3/21/2018	Maxim Group	Set Price Target	Buy	$9.00	Low	i Rating by Jason Kolbert at Maxim Group
3/8/2018	Maxim Group	Set Price Target	Buy	$9.00	High	i Rating by Jason Kolbert at Maxim Group
12/27/2017	Maxim Group	Set Price Target	Buy	$9.00	Medium	i Rating by Jason Kolbert at Maxim Group
10/16/2017	Maxim Group	Set Price Target	Buy	$9.00	N/A	i Rating by Jason Kolbert at Maxim Group
8/16/2017	Maxim Group	Set Price Target	Buy	$8.00 ➝ $9.00	Low	i Rating by Jason Kolbert at Maxim Group
7/22/2017	Maxim Group	Set Price Target	Buy	$8.00	Medium	i Rating by Jason Kolbert at Maxim Group
6/13/2017	Maxim Group	Set Price Target	Buy	$8.00	Low	i Rating by Jason McCarthy at Maxim Group
5/15/2017	Maxim Group	Set Price Target	Buy	$8.00	Medium	i Rating by Jason Kolbert at Maxim Group
4/19/2017	Maxim Group	Set Price Target	Buy	$8.00	Low	i Rating by Jason Kolbert at Maxim Group
3/30/2017	Maxim Group	Boost Price Target	Buy	$6.00 ➝ $8.00	High	i Rating by Jason Kolbert at Maxim Group
3/8/2017	Maxim Group	Reiterated Rating	Buy	$6.00	Medium	i Rating by Jason Kolbert at Maxim Group
12/20/2016	Maxim Group	Boost Price Target	Buy	$5.00 ➝ $6.00	N/A	i Rating by Jason Kolbert at Maxim Group
12/14/2016	Maxim Group	Set Price Target	Buy	$5.00 ➝ $6.00	N/A	i Rating by Jason Kolbert at Maxim Group
8/11/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by jason kolbert at Maxim Group
7/18/2016	Maxim Group	Reiterated Rating	Buy	$5.00	N/A	i Rating by Jason Kolbert at Maxim Group

(Data available from 6/14/2016 forward)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Today's Range

Now: $3.91

$3.88

$4.06

50 Day Range

MA: $3.48

$3.01

$3.96

52 Week Range

Now: $3.91

$2.92

$17.95

Volume

365,697 shs

Average Volume

843,572 shs

Market Capitalization

$142.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Frequently Asked Questions

What sell-side analysts currently cover shares of Brainstorm Cell Therapeutics?

The following Wall Street analysts have issued research reports on Brainstorm Cell Therapeutics in the last twelve months: Maxim Group.
View the latest analyst ratings for BCLI.

What is the current price target for Brainstorm Cell Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Brainstorm Cell Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 206.9%. Maxim Group has the highest price target set, predicting BCLI will reach $12.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $12.00 for Brainstorm Cell Therapeutics in the next year.
View the latest price targets for BCLI.

What is the current consensus analyst rating for Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCLI will outperform the market and that investors should add to their positions of Brainstorm Cell Therapeutics.
View the latest ratings for BCLI.

What other companies compete with Brainstorm Cell Therapeutics?

Other companies that are similar to Brainstorm Cell Therapeutics include Codiak BioSciences, Autolus Therapeutics, Harpoon Therapeutics, Gritstone bio, Oyster Point Pharma, Ikena Oncology, Achilles Therapeutics, Lineage Cell Therapeutics, Black Diamond Therapeutics, Solid Biosciences, Outlook Therapeutics, Opthea, AVROBIO, SQZ Biotechnologies and Adverum Biotechnologies.

How do I contact Brainstorm Cell Therapeutics' investor relations team?

Brainstorm Cell Therapeutics' physical mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is 201-488-0460 and its investor relations email address is [email protected] The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.